Pancreatic cancer treatment device company OncoSil Medical (ASX:OSL) has completed patient recruitment for the TRIPP-FFX clinical trial.
The TRIPP-FFX study is a prospective, multicentre clinical trial evaluating the safety and efficacy of the OncoSil device used in combination with FOLFIRINOX chemotherapy in patients with locally advanced pancreatic cancer (LAPC).
This study, like the PANCOSIL Investigator Initiated Study, which also recently met its patient recruitment target, is a part of OncoSil's clinical development strategy. At least 88 patients have been recruited into the TRIPP-FFX study across 15 hospitals located in Europe and Australia.
The study forms part of OncoSil’s ongoing plan to build the clinical evidence base necessary to support the broader adoption of the OncoSil device, in addition to standard-of-care chemotherapy.
OncoSil said it expects data from the TRIPP-FFX study to become available in early calendar 2026.
Giuseppe Malleo, one of the two coordinating investigators of the TRIPP-FFX study and Associate Professor of Surgery at the University of Verona, said, “The TRIPP-FFX study represents an important step in exploring new therapeutic options for patients with locally advanced pancreatic cancer. The integration of the OncoSil device with FOLFIRINOX chemotherapy could offer a meaningful improvement in clinical outcomes. We are pleased to have completed recruitment and look forward to analysing the results."
OncoSil Medical CEO and Managing Director, Nigel Lange, said, "We are thrilled by the speed at which patient recruitment for the TRIPP-FFX clinical trial has occurred. It means that yet another milestone in our well-articulated clinical development strategy for the OncoSil device has been met. I personally want to thank our clinical partners for their sustained efforts to deliver the study’s target patient recruitment level. Because of their hard work and dedication, the strong momentum behind OncoSil Medical team’s commitment to demonstrate the multiple ways its innovative treatment platform will continue to occur at a rapid pace. We now look forward to the data readout from the study. In the meantime, we will strive to realise other development and commercialisation milestones for the OncoSil device, which is improving outcomes for patients with unresectable locally advanced pancreatic cancer."